30 6月 2026 by admin in UncategorizedComments Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
09 6月 2026 by admin in UncategorizedComments Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long- Acting Anti-TSLP Antibody WIN378
08 6月 2026 by admin in UncategorizedComments China NMPA Grants IND Clearance to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer
04 6月 2026 by admin in UncategorizedComments Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
01 6月 2026 by admin in UncategorizedComments Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
